Forbius has deep expertise in targeting the TGF-beta and EGFR pathways, which are drivers of multiple life-threatening conditions, including cancer and fibrosis. By using multiple complementary platform technologies, Forbius' team overcame barriers that prevented the development of effective therapeutics targeting these pathways.